Massachusetts Financial Services Co. MA Has $45.69 Million Stock Holdings in Certara, Inc. (NASDAQ:CERT)

Massachusetts Financial Services Co. MA raised its stake in shares of Certara, Inc. (NASDAQ:CERT) by 40.7% in the third quarter, HoldingsChannel reports. The institutional investor owned 3,901,898 shares of the company’s stock after purchasing an additional 1,128,006 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Certara were worth $45,691,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of CERT. Daventry Group LP boosted its position in Certara by 153.0% during the second quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock valued at $18,124,000 after purchasing an additional 791,405 shares during the last quarter. Kopion Asset Management LLC purchased a new stake in shares of Certara during the 3rd quarter worth about $4,457,000. Sei Investments Co. lifted its holdings in shares of Certara by 39.5% during the 2nd quarter. Sei Investments Co. now owns 997,871 shares of the company’s stock valued at $13,821,000 after buying an additional 282,357 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Certara by 9.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after buying an additional 273,095 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG acquired a new position in Certara in the third quarter worth approximately $1,513,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Performance

Shares of CERT opened at $10.36 on Monday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara, Inc. has a one year low of $9.41 and a one year high of $19.87. The company’s fifty day moving average price is $10.79 and its 200 day moving average price is $13.17. The company has a market capitalization of $1.67 billion, a PE ratio of -51.80, a price-to-earnings-growth ratio of 4.94 and a beta of 1.51.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. During the same period in the previous year, the business posted $0.06 EPS. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. As a group, analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

CERT has been the subject of a number of analyst reports. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Friday, September 27th. Robert W. Baird reduced their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Finally, Barclays decreased their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $15.92.

Insider Buying and Selling at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. The trade was a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares of the company’s stock, valued at $1,125,658.16. This represents a 33.94 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.